Zymeworks

$48.37
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$3.79 (-7.27%) Today

$0.00 (0.00%) As of 12:00 PM UTC after-hours

Why Robinhood?

You can buy or sell Zymeworks and other stocks, options, and ETFs commission-free!

About ZYME

Zymeworks Inc., also called Zymeworks, is a clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of biotherapeutics. Its product, ZW25 and ZW49 are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. The listed name for ZYME is Zymeworks Inc.

CEO

Ali Tehrani

Employees

256

Headquarters

Vancouver, British Columbia

Founded

2003

Market Cap

2.19B

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

651.34K

High Today

$51.19

Low Today

$47.37

Open Price

$50.96

Volume

548.95K

52 Week High

$59.03

52 Week Low

$20.33

Collections

ZYME News

Reuters1h

Russian court to hear Kremlin foe Navalny's arrest appeal on Jan 28 - ally

TipRanks The biotech sector has started the year with a bang. The industry benchmark, iShares NASDAQ Biotechnology ETF (IBB), is up ~11% so far in January -- f

Analyst Ratings

82%

of 11 ratings

Buy

82%

Hold

18%

Sell

ZYME Earnings

-$1.43

-$0.95

-$0.48

$0.00

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Mar 1, After Hours